title: Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.
abstract: Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases. The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
authors.affiliation: IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas ICH 20089, Rozzano, Milan, Italy. sdanese@hotmail.com.
authors.forename: Manol
authors.initials: M
authors.lastname: Jovani
authors.forename: Gionata
authors.initials: G
authors.lastname: Fiorino
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D018793:Interleukin-13 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D001688:Biological Products; D018793:Interleukin-13; C561806:lebrikizumab